# Hepatitis C Treatment in PWIDs: MAT or Syringe Exchange Assisted-therapy vs Standard of Care

> **NCT03093415** · PHASE4 · COMPLETED · sponsor: **Oregon Health and Science University** · enrollment: 100 (actual)

## Conditions studied

- Hepatitis C
- Substance Use Disorders
- Substance Abuse, Intravenous

## Interventions

- **DRUG:** elbasvir-grazoprevir (50 mg/100 mg)

## Key facts

- **NCT ID:** NCT03093415
- **Lead sponsor:** Oregon Health and Science University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-30
- **Primary completion:** 2019-06-06
- **Final completion:** 2019-06-06
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2020-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03093415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03093415, "Hepatitis C Treatment in PWIDs: MAT or Syringe Exchange Assisted-therapy vs Standard of Care". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03093415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*